TRIAL DETAIL

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic

Drug:
Trial Name:
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic
NCT#:
Conditions:
Gastrointestinal Stromal Tumor or Sarcoma
Status:
Completed
Phase:
1
Start Date 07/10/2012
Age of Trial (yrs) 12.5
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT inhibitor + CTLA-4 inhibitor
Strategy:
Block KIT + Stimulate the immune system
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
NCI-2012-01165, 12-083, U01CA069856
Sponsor:
National Cancer Institute
Patient Contact:
Sandra P. D'Angelo 646-888-4159 dangelos@mskcc.org
Contact email:
dangelos@mskcc.org
Contact Phone:
646-888-4159
Randomized:
IV or Oral:
Oral Intravenous
Trial Notes:
This is a phase I trial combining dasatinib (a KIT/PDGFRA/SCR/ABL inhibitor) with ipilimumab, a CTLA-4 inhibitor (immunotherapy that activates T cells). This trial is open to both GIST patients as well as other sarcoma patients.
The trial will have two stages. During the first stage, both Gleevec-naive as well as Gleevec/Sutent resistant patients may enter the trial. After the maximum tolerated dose of the combination is determined, the second stage will be limited to Gleevec/Sutent-resistant patients.

Trial Links
 

Trial Results
 
 

Drug Information
Dasatinib (Sprycel)
 
Ipilimumab (Vervoy)
 
Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido (full text article)
 
MSKCC opens new immunotherapy trial for GIST
 

Trial Sites

Name
Address
City
State
Zip
Country
1275 York Ave
New York
NY
10065
USA